Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197402 | 0.90 | ALDH1A1 (0.52) | ALDH1A1HPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL2497708 | 0.88 | PTGDR2 (0.56) | ALDH1A1HPGDCYP2C9PTGDR2 | |
| SCHEMBL12197421 | 0.83 | POLB (0.42) | MAPTLMNAGAAPTGDR2 | |
| SCHEMBL12197397 | 0.82 | PTGDR2 (0.48) | GAACYP2C9PTGDR2 | |
| SCHEMBL12197427 | 0.80 | PTGDR2 (0.43) | GAACYP2C9PTGDR2 | |
| SCHEMBL2496926 | 0.79 | PTGDR2 (0.48) | ALDH1A1HPGDNPC1SMN1; SMN2RAB9A | |
| SCHEMBL12197401 | 0.79 | CYP3A4 (0.52) | ALDH1A1GAACYP2C9PTGDR2 | |
| SCHEMBL12197447 | 0.78 | GAA (0.52) | ALDH1A1GAACYP2C9PTGDR2 | |
| SCHEMBL12197398 | 0.78 | PTGDR2 (0.50) | GAACYP2C9PTGDR2 | |
| SCHEMBL136044 | 0.77 | GAA (0.51) | ALDH1A1GAACYP2C9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524748-B2 | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110245303-A1 | HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245303-A1 | HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | ALDH1A1 1889/4885HPGD 72/4885NPC1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.